financetom
Business
financetom
/
Business
/
OpenAI's Altman envisions Stargate-like programme for Europe
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
OpenAI's Altman envisions Stargate-like programme for Europe
Feb 7, 2025 8:47 AM

BERLIN, Feb 7 (Reuters) - OpenAI CEO Sam Altman on

Friday signaled willingness to bring a Stargate-like artificial

intelligence program to Europe, saying his company would "love"

to do a Stargate Europe.

Stargate is a U.S. venture launched by U.S. President Donald

Trump that involves backers like OpenAI, Softbank and

Oracle. Up to $500 billion will be invested in AI

infrastructure over the next five years.

"We need help," Altman told students at a panel discussion

at the Technical University of Berlin, stressing that it would

be up to Europeans to decide how they want to set their rules

for AI technology. "We'll obviously comply with whatever they

are," said Altman. According to Altman, it would be in Europe's

best interest to adopt AI and not lag behind the rest of the

world.

OpenAI will open a new office in Munich, Germany, as part of

its European expansion plans, the company announced in a press

release. "Opening our first office in Germany means we can help

even more people, businesses, institutions benefit from AI's

possibilities," said Altman.

OpenAI has expanded to the European continent in recent

years, announcing offices in Dublin and London in 2023 and two

additional ones in Paris and Brussels in 2024.

On Monday, Altman is expected to attend an AI summit in

Paris, which will also be attended by several European heads of

state and other government officials.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Intel Updates Viewed in 'Positive Light' But Not Sufficient to Overcome Challenges, Truist Says
Intel Updates Viewed in 'Positive Light' But Not Sufficient to Overcome Challenges, Truist Says
Sep 17, 2024
10:20 AM EDT, 09/17/2024 (MT Newswires) -- Intel's ( INTC ) recent business update announcements are viewed in a positive light but are not sufficient to overcome issues the company is facing, Truist Securities said in a note Tuesday. The highlights include Intel Foundry operating as an independent unit; the company receiving up to $3 billion in US government chip...
INmune Bio Says AD02 Trial for Alzheimer's Disease Reveals Strong Performance of EMACC Cognitive Measure
INmune Bio Says AD02 Trial for Alzheimer's Disease Reveals Strong Performance of EMACC Cognitive Measure
Sep 17, 2024
10:19 AM EDT, 09/17/2024 (MT Newswires) -- INmune Bio ( INMB ) said Tuesday that additional analysis from its AD02 phase 2 trial for Alzheimer's disease showed exceptional performance of the Early AD/MCI Alzheimer's Cognitive Composite, or EMACC, measure. The analysis revealed a highly significant correlation between baseline scores on EMACC and the Clinical Dementia Rating-Sum of Boxes, or CDR-SB,...
Uber to roll out 'verified' rider badge, trip recording features in US
Uber to roll out 'verified' rider badge, trip recording features in US
Sep 17, 2024
Sept 17 (Reuters) - Uber ( UBER ) is rolling out features that would allow its drivers to see verified badges on customer profiles and record trips on their smartphones instead of a dashcam, the ride-hailing firm said on Tuesday. This is expected to improve safety of drivers and comes against the backdrop of a 2021-22 safety report by Uber...
Capricor Therapeutics, Nippon Shinyaku Sign Binding Term Sheet for Commercialization of Duchenne Muscular Dystrophy Treatment in Europe
Capricor Therapeutics, Nippon Shinyaku Sign Binding Term Sheet for Commercialization of Duchenne Muscular Dystrophy Treatment in Europe
Sep 17, 2024
10:31 AM EDT, 09/17/2024 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Tuesday it signed a binding term sheet with Japanese pharmaceutical firm Nippon Shinyaku to commercialize and distribute Capricor's Duchenne muscular dystrophy treatment deramiocel in Europe. Capricor said the potential deal that the term sheet covers is similar to the existing commercialization and distribution agreements with Nippon Shinyaku...
Copyright 2023-2025 - www.financetom.com All Rights Reserved